Search company, investor...

Genaissance Pharmaceuticals

Founded Year



Unattributed VC - III | Alive

Total Raised


Last Raised

$25M | 14 yrs ago

About Genaissance Pharmaceuticals

Personalized medicine through population genomics and informatics.

Headquarters Location

One Gateway Center Suite 702

Newton, Massachusetts, 02458,

United States


Missing: Genaissance Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Genaissance Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Genaissance Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Genaissance Pharmaceuticals is included in 1 Expert Collection, including Omics.



1,267 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

Latest Genaissance Pharmaceuticals News

Clinical Data acquires Genaissance

Apr 22, 2014

23-Jun-20052005-06-23T00:00:00Z Related tags: Genaissance, Clinical, Data Clinical Data is to acquire Genaissance Pharmaceuticals in a deal worth $56 million (€46.3 million). The merger allows Clinical Data to add pharmacogenomic diagnostics and tools to its burgeoning portfolio as it prepares to enter the molecular diagnostics market. On a strategic level, the deal could be seen as an attempt to gain a foothold in a $6.5 billion market. According to Jain PharmaBiotech, this represents approximately 3.3 per cent of the total diagnostics market and approximately 14 per cent of the in vitro diagnostic market. The molecular diagnostics market is expected to increase to $12 billion by 2010 and $35 billion by 2015. A major portion of it can be attributed to advances in genomics and proteomics. Biochip and nanobiotechnology are expected to make a significant contribution to the growth of molecular diagnostics. Under the terms of the agreement, Clinical Data will acquire two clinically relevant molecular diagnostic tests available commercially and additional developmental opportunities in the CNS and cardiovascular areas. Israel Stein, president and chief executive officer of Clinical Data said: "The acquisition will allow us to leverage our market knowledge and experience with GNSC's platform. " "Genaissance Pharmaceuticals is a strong strategic fit, enabling us to enter the molecular diagnostics market in a meaningful way," he added. Stein added that in purchasing Genaissance, the company hoped to enter the theranostics sector - guiding pharmaceutical therapy through the use of diagnostic tests. This, he said required the integration of regulatory, research, clinical and marketing approaches. "We strongly believe the benefits of genetically targeted pharmacotherapy will undoubtedly become essential to disease prevention and treatment," he added. Under the terms of the agreement, announced Tuesday the deal is an all-stock transaction valued at $56 million. Genaissance shareholders will own 40 per cent of the combined company when the deal closes sometime in the fourth quarter. The acquisition will also see a change in personnel with current Genaissance board members Kevin Rakin and Joseph Klein joining the CLDA's board of directors. Burton Sobel, Amidon professor, physician-in-chief, and Professor of Biochemistry at the University of Vermont, will also join the Board, bringing the total number of directors to seven. Genaissance focuses on integrating the use of single-nucleotide polymorphisms (SNPs) into the development of DNA-based diagnostic and therapeutic products. This merger illustrates the growing recognition of an emerging pharmacogenomics market. Randal Kirk, chairman of Clinical Data said: "Pharmacogenomics is poised to play a significant role in healthcare and is a growing area of research that is gaining traction with pharmaceutical companies and clinicians. " "Through this acquisition, Clinical Data is building on its strong existing foundation to enter new markets and continue to be an innovator in improving patient healthcare," he added. This content is copyright protected However, if you would like to share the information in this article, you may use the headline, summary and link below: Clinical Data acquires Genaissance 23-Jun-2005 Clinical Data is to acquire Genaissance Pharmaceuticals in a deal worth $56 million (€46.3 million). The merger allows Clinical Data to add pharmacogenomic diagnostics and tools to its burgeoning portfolio as it prepares to enter the molecular diagnostics market. Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions Related news:

Genaissance Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Genaissance Pharmaceuticals founded?

    Genaissance Pharmaceuticals was founded in 1969.

  • Where is Genaissance Pharmaceuticals's headquarters?

    Genaissance Pharmaceuticals's headquarters is located at One Gateway Center, Newton.

  • What is Genaissance Pharmaceuticals's latest funding round?

    Genaissance Pharmaceuticals's latest funding round is Unattributed VC - III.

  • How much did Genaissance Pharmaceuticals raise?

    Genaissance Pharmaceuticals raised a total of $105.38M.

  • Who are the investors of Genaissance Pharmaceuticals?

    Investors of Genaissance Pharmaceuticals include Third Security, Pequot Capital Mangement, Hudson Bay Capital Management, Downsview Capital, Nite Capital Management and 9 more.

  • Who are Genaissance Pharmaceuticals's competitors?

    Competitors of Genaissance Pharmaceuticals include NGM Biopharmaceuticals, Motif BioSciences, PregLem, EGeen International, Global Cell Solutions and 11 more.

Compare Genaissance Pharmaceuticals to Competitors

Avestha Gengraine Technologies

Avestha Gengraine Technologies is a biotechnology & bioinformatics company, focusing on the convergence between food, pharmaceuticals and clinical genomics leading to preventive personalized medicine. . Avesthagen was founded by Dr. Villoo Morawala-Patell in 1998, on the premise that the time was ripe for India to establish its own research and discovery based biotechnology industry. Avesthagen aims to provide solutions for global challenges in agriculture & health problems in the areas of degenerative conditions, metabolic disorders and infectious diseases.

Bauer BioMedical

Bauer BioMedical, LLC is at the forefront of technological advances in the field of Genetic Translational Medicine. The company is in the process of finding applications for the company's Intellectual Property in the fields of Preemptive Medicine and Theranostics.

MODA Technology Partners

MODA Technology Partners is a provider of informatics solutions for pharmaceutical and biotechnology quality manufacturing

Global Cell Solutions

Global Cell Solutions, headquartered in Charlottesville, Virginia, is focused on the application of a improved patent-pending cell culturing technique. Global Cell is positioned to be an integral partner to scientific s in medicine, research, biotechnology, pharmaceuticals and the emerging field of orthobiologics.


Idiomics, LLC is a biotechnology company providing health providers, healthcare payors and pharmaceutical companies informatics and biotechnology tools and platforms to personalize medical care to the individual patient.

Cell Line Genetics Logo
Cell Line Genetics

Cell Line Genetics aims to provide services and products to support research institutions, as well as biotechnology and pharmaceutical companies focused on embryonic stem cell and cancer research.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.